Painreform is trading 7.47% higher at $1.00, with broader biotech strength lifting the sector. - Biotech rose 2.07% during regular trading, and trading remains active in the open market. - No verified company-specific announcement dated September 23, 2026, was identified; the catalyst assessment is medium-confidence. - The latest indexed company coverage concerns GridFeed’s AI data-center power-optimization strategy, announced September 16, rather than a new catalyst today.